Sarepta Therapeutics, Inc. (SRPT): Cost of Revenue
$25.50M
Year ended 2025-12-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $25.50M | n/a | 2026-03-02, From 2025-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $25.50M | n/a |
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $1.91B | +7.4% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $384.40M | +24.1% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.01B | +12.2% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $717.44M | +23.6% |
| Alkermes plc. (ALKS) | 2025-12-31 | $196.46M | -19.9% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $677.17M | +120.9% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $246.00M | +6.5% |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $2.76B | -2.5% |
Compare SRPT, AMRX, UTHR, PAHC side by side · Screen every company in Pharmaceutical Preparations ↗